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The fabrication and validation of the first semi-liquid nonprotein nucleating
agent to be administered automatically to crystallization trials is reported. This
research builds upon prior demonstration of the suitability of molecularly
imprinted polymers (MIPs; known as ‘smart materials’) for inducing protein
crystal growth. Modified MIPs of altered texture suitable for high-throughput
trials are demonstrated to improve crystal quality and to increase the probability
of success when screening for suitable crystallization conditions. The application
of these materials is simple, time-efficient and will provide a potent tool for
structural biologists embarking on crystallization trials.
1. Introduction
Statistics indicate that the success rate of obtaining diffraction-
quality crystals from purified proteins has stagnated at 20%
for over a decade (Target Track PSI; http://sbkb.org/tt/). This
has fuelled methods development and advances including the
application of porous nucleants (Chayen et al., 2006; Khurshid
et al., 2014), the lipidic cubic phase (Nollert, 2004; Caffrey &
Cherezov, 2009), novel microfluidic platforms (Zheng et al.,
2003; Shim et al., 2007), commercial screens of greater potency
(Newman et al., 2005; Gorrec, 2009) and novel seeding
protocols (Georgiev et al., 2006; D’Arcy et al., 2007), which
have been reported with success. In order for methodological
advances to be of benefit to the wider community it is
imperative that they be adapted to high throughput.
This article details the fabrication and validation of the first
semi-liquid nonprotein nucleant compatible with automated
crystallization trials. Nucleants are materials which induce
heterogeneous nucleation of protein crystals in a controlled
manner. Nucleant research has advanced significantly since
pioneering studies in 1988 (McPherson & Shlichta, 1988). The
current trend for nonprotein porous materials has resulted in a
plethora of candidate nucleants (Asanithi et al., 2009; Rong et
al., 2004; Curcio et al., 2003; Sugahara et al., 2008; Kertis et al.,
2012; Saridakis & Chayen, 2009) and a commercial product.
Several of these materials have been successful but are not
readily amenable to automation.
In 2011, we reported the application of molecularly
imprinted polymers (MIPs; known as ‘smart materials’) as
nucleants for protein crystallization (Saridakis et al.,
2011). These polyacrylamide-based nucleating agents were
ISSN 1399-0047
demonstrated to induce the nucleation of nine proteins under
metastable conditions as well as increasing the number of
crystal leads obtained from screening. MIPs were created
by imprinting a protein in a polymer and then removing it,
leaving behind specific cavities which would then rebind this
protein when introduced into a crystallization trial (Fig. 1). It
was initially envisaged that these materials would be specific,
in that an MIP would only be suitable for the cognate protein
it was imprinted with. In practice this has not been the case,
with proteins of similar molecular weight to the cognate
nucleating successfully. This correlation between the cavity/
pore size and the hydrodynamic radius of protein molecules
in solution is a recurring theme in heterogeneous nucleant
research (Page & Sear, 2006).
The gel-like consistency of MIPs, similar to that of a high-
molecular-weight PEG (and their efficacy as a nucleating
agent) makes them promising candidates for automated
crystallization trials. This very consistency is also a cause for
concern, with preliminary trials indicating that MIPs would
block robotic dispensing tips despite viscosity adjustments.
Accordingly, the primary aim of this research was the
production of a less viscous MIP which could be dispensed
automatically whilst ensuring the integrity of the MIP as a
nucleating agent.
The benefits of having a ‘standalone’ nucleant which can be
added indiscriminately to crystallization trials, independent
of the protein (or the crystallization cocktail for that matter),
are numerous. Previous attempts at robotically dispensing
heterogeneous nucleants have involved solid materials being
crushed and dispensed as a suspensions (Thakur et al., 2007;
D’Arcy et al., 2004; Stewart et al., 2011). This raises questions
as to which solvent to use, the optimal dilution of the
suspension, the volume to dispense, whether this will dilute/
bias the crystallization droplets and whether there is a
reproducible amount of nucleant per suspension volume. If
the nucleant is added to the protein stock prior to dispensing,
the topographical features of the nucleant become saturated
with protein, potentially reducing their efficacy. The applica-
tion of MIPs bypasses these concerns.
2. Materials and methods
2.1. Protein information
Six proteins were tested. Model proteins were utilized for
automated screening trials with MIPs to benchmark the
technique. These included lysozyme (hen egg white; Sigma,
catalogue No. L7651), thaumatin (from Thaumatococcus
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Figure 1
Fabrication of MIPs. Schematic illustration of the steps involved in preparing MIPs for crystallization studies. The initial assembly between the protein
template and monomer is advanced through the presence of a polymerizing cross-linker. The protein is then eluted, leaving a protein-specific cavity
known as a ‘ghost site’ (adapted from http://www.biotage.com/product-page/mips---molecularly-imprinted-polymers).
daniellii; Sigma, catalogue No. T7638), trypsin (bovine
pancreatic; Sigma, catalogue No. T4665) and haemoglobin
(bovine; Sigma, catalogue No. H2500). The model proteins
were prepared at the required concentrations in deionized
water. Two target proteins, Chlamydia trachomatis plasmid-
encoded immunodominant antigen (Pgp3; 7 mg ml1 in
220 mM sodium chloride, 50 mM Tris–HCl pH 7.5 with 5 mM
DTT) and human macrophage migration inhibitory factor
(MIF; 11 mg ml1 in 20 mM Tris pH 7.5, 20 mM sodium
chloride), were utilized for the automated optimization trials
with MIPs.
2.2. Fabrication of modified MIPs
Modified, less viscous MIPs were prepared for five proteins:
haemoglobin, trypsin, lysozyme, Pgp3 and MIF. These
MIPs were synthesized using acrylamide monomers (AA;
71.1 g mol1; Sigma–Aldrich UK) and N,N0-methylenebis-
acrylamide (bis-AA) as a cross-linker (154.18 g mol1; Sigma–
Aldrich UK). Acrylamide-based polymers are nitrogen-
containing members of the acrylate family and are suitable
imprinting matrices for biological molecules as they are water-
compatible, economical, easily produced and can be deriva-
tized to introduce functional groups (namely hydroxyl,
carboxylate and amino groups) to better engineer comple-
mentary interactions between the template molecule and the
polymer (Liao et al., 1996).
5.4 mg (0.76M) AA and 0.6 mg (38.9 mM) bis-AA cross-
linker were mixed with 0.6 mg ml1 template protein
(haemoglobin, 64.5 kDa, 9.3 mM; trypsin, 23.8 kDa, 25.2 mM;
lysozyme, 14.3 kDa, 41.96 mM; Pgp3, 28 kDa, 30.36 mM; MIF,
12.3 kDa, 48.78 mM) along with Milli-Q water, initiator [2 ml
of a 10%(w/v) ammonium persulfate APS solution, 8.77 mM;
Sigma–Aldrich UK] and catalyst [2 ml of a 5%(v/v) N,N,N,N-
tetramethylethyldiamine (TEMED) solution, 8.61 mM; Sigma–
Aldrich UK] to give final volumes of 100 ml. The solutions
were then purged with nitrogen for 5 min and allowed to
polymerize overnight at room temperature (22C). A final
gel density of 6%T [percentage (w/v) of AA plus bis-AA in
the final monomer solution] and a final cross-linking density of
10%C (percentage by mass of bis-AA relative to the total
mass of AA plus bis-AA) was obtained for AA/bis-AA (w/v)s.
The molar ratios of AA monomer and bis-AA cross-linker to
template protein were 81 720:1 and 4183:1 for haemoglobin,
30 159:1 and 1544:1 for trypsin, 18 112:1 and 927:1 for lyso-
zyme, 25 033:1 and 1281:1 for Pgp3 and 15 580:1 and 797:1 for
MIF.
For every modified MIP created, a non-imprinted control
polymer (NIP) was prepared in an identical manner but in the
absence of template protein.
After polymerization, the modified MIPs were conditioned
(as detailed in Supporting Information xS1.1) before being
diluted in Milli-Q water at ratios of 1:2, 1:3 and 1:5 [MIP:water
(w:v)] and stored at 4C for crystallization trials. The subse-
quent rebinding effect of the conditioned and equilibrated
MIPs and NIPs were characterized as detailed in Supporting
Information xS1.2.
2.3. Crystallization robotics
Mosquito (TTP Labtech, UK) and Oryx (Douglas Instru-
ments, UK) robots were utilized to test the high-throughput
addition of MIPs to sitting-drop vapour-diffusion crystal-
lization trials. 96-well MRC plates were employed as standard
(Molecular Dimensions, UK).
2.4. Preliminary trials
Thaumatin and trypsin were employed for initial trials
which involved determining (i) whether the modified MIPs
prompted the nucleation of crystals, (ii) which of the MIP
dilutions was most suitable, (iii) the optimal volume of MIPs
to add to the crystallization trials and (iv) whether the total
drop volume had any bearing on the efficacy of the nucleant.
A series of identical drops were prepared corresponding to a
known metastable condition for 30 mg ml1 thaumatin
(0.24M sodium potassium tartrate, 0.1M bis-tris propane pH
6.8) and 50 mg ml1 trypsin [13%(w/v) PEG 8000, 0.1M Tris
pH 7.5]. 190, 185, 180 and 175 nl crystallization droplets were
dispensed for each protein, where the protein and crystal-
lization condition were mixed in a 1:1 ratio. Cognate MIPs
volumes of 10, 15, 20 and 25 nl were added to these respective
droplets, ensuring a total trial volume of 200 nl. 1:2, 1:3 and 1:5
samples of each cognate MIP were tested such that eight
repeats were dispensed for each combination. This protocol
was repeated for 400 nl trials, where 10, 20, 30 and 40 nl
volumes of MIPs were added to 390, 380, 370 and 360 nl
crystallization droplets, respectively. Two control drops were
dispensed for each condition: one where no MIP was inserted
and a second where an NIP was inserted instead of an MIP.
2.5. Automated screening trials
Four model proteins and three MIPs were utilized for
the automated screening trials. Commercially available 96-
condition screens (Crystal Screen HT, Hampton Research
USA) were dispensed for 30 mg ml1 lysozyme, 30 mg ml1
thaumatin, 50 mg ml1 trypsin and 60 mg ml1 haemoglobin.
Protein was mixed in a 1:1 ratio with each screen condition to
form a 180 nl drop. 20 nl of a 1:2 MIP sample was added
robotically to this 180 nl drop volume, ensuring a total trial
volume of 200 nl. Trypsin-MIP, lysozyme-MIP and haemo-
globin-MIP were tested for each protein. Comparison was
made with control drops which contained no MIPs or
contained NIPs instead of MIPs.
2.6. Automated optimization trials
One model protein (trypsin) and two target proteins (Pgp3
and MIF) were used to validate the modified MIPs for auto-
mated optimization trials. These trials involved the exploita-
tion of known ‘hit’ conditions for each protein and the
metastable zone of the phase diagram. The ‘hit’ conditions
and the robotic determination of metastability are detailed in
Supporting Information xxS1.3 and S1.4, respectively.
7 mg ml1 Pgp3 and 11 mg ml1 MIF were dispensed
against their corresponding ‘hit’ conditions, forming 180 nl
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crystallization drops. The ‘hit’ condition was dispensed neat
and in 5% dilutions down to 45%. Eight repeats were
dispensed at each dilution. 20 nl of a 1:2 cognate MIP was then
added to form 200 nl trials.
As an alternative, a working phase diagram (Khurshid et al.,
2014) was prepared for 50 mg ml1 trypsin by dispensing 90 nl
of the protein into 90 nl of its ‘hit’ condition (where the
primary precipitant PEG 8000 was decreased in 1% steps from
16 to 10%). Eight repeats were dispensed of each concentra-
tion and 20 nl trypsin-MIP was added to each repeat. The
same grid was repeated utilizing haemoglobin-MIP to deter-
mine how effective a noncognate MIP with a larger cavity
would be.
2.7. Diffraction analysis
The diffraction resolution limits of the crystals obtained
from the automated optimization trials were determined using
an ‘in-house’ Rigaku MicroMax-007 HFM X-ray generator
operating at 40 kVand 30 mAwith VHF optics, a Saturn 944+
CCD detector and an Oxford Cryosystems 700 liquid-nitrogen
cryostream. Comparison was made with crystals obtained in
control drops at the lowest supersaturation at which crystal-
lization would occur spontaneously. 12 Pgp3 crystals and eight
MIF crystals were tested.
3. Results and discussion
The addition of MIPs to screening and optimization trials
using robots was successfully demonstrated for a range of
model and target proteins. Before discussing the results
obtained from the automated screening and optimization
trials, it is important to shed light upon the results obtained
from the preliminary trials, as they provided the basis for
performing these later experiments in an optimal fashion.
3.1. Preliminary trials
The first result to bear in mind is that the modified MIPs
were much less viscous than the original gel-like MIPs, with
a consistency similar to that of a low-molecular-weight PEG.
The modified MIPs reproducibly facilitated crystal growth
under metastable conditions for thaumatin and trypsin. Each
of the MIP dilutions was successful in this regard. The 1:2 and
1:3 samples in particular provided the most reproducible
results, whilst the 1:5 sample was not as efficient at lower
supersaturation. This lack of efficiency indicates a probable
loss of MIP cavity integrity upon excessive dilution. The 1:2
sample, although the most viscous of the modified MIPs, did
not block the dispensing tips, and as such a 1:2 MIP sample
was chosen for all subsequent trials.
The optimal volume of MIPs to incorporate into trials was
found to be10% of the total droplet volume. This tallies with
the research performed with the original gel-like MIPs.
Although the crystallization outcomes of the trials performed
with varying MIP volumes greater than 10% were similar, it is
preferable to prevent excessive dilution of the crystallization
droplet with the liquid nucleant. Furthermore, dispensing less
than 10% becomes a technical challenge when the total drop
volume is 200 nl, as the accuracy plummets drastically. The
irregular results obtained with 10 and 15 nl nucleant volumes
corroborate this. When the total drop volume is 400 nl this is
not an issue. However, most laboratories screen using 200 nl
drops to minimize protein consumption, and as such an 180 nl
crystallization droplet with an added 20 nl MIPs volume is
recommended.
The effect of drop volume on the nucleating ability of the
MIPs was found to be negligible. The results obtained with
200 and 400 nl trial volumes were identical and extrapolate
directly to the results obtained at 600 nl using the original gel-
like MIPs. As such, if the researcher wishes to utilize a greater
drop volume to optimize crystal size, decreased MIP efficacy
will not be an issue.
3.2. Automated screening trials
Having determined that the modified MIPs would function
as nucleating agents and having determined the optimal
conditions for their use, automated screening trials were
commenced. Table 1 clearly indicates the ability of MIPs to
increase the number of crystal ‘hits’ obtained. 12 new ‘hits’
were obtained for lysozyme, 15 for thaumatin (Fig. 2), four for
trypsin and two for haemoglobin. The striking result is that
haemoglobin-MIP, the MIP with the largest cavities, gave the
most hits overall. For example, when screening with thaumatin
at 30 mg ml1, nine new conditions were discovered using
haemoglobin-MIP, four with lysozyme-MIP and five with
trypsin-MIP. The caveat in this instance being that the crystal
‘hits’ obtained were not as visually promising as those with
research papers
Acta Cryst. (2015). D71, 534–540 Khurshid et al.  Smart materials for protein crystallization 537
Figure 2
Thaumatin screening. Thaumatin crystals grown using a trypsin-MIP.
These crystals were obtained using a screen condition that did not yield
crystals in control drops [0.2M ammonium sulfate, 30%(w/v) PEG 8000].
The presence of MIPs facilitated thaumatin crystal formation in a further
14 screen conditions where controls did not form, as detailed in Table 1.
14 of the 15 conditions did not contain tartrate, which is the most potent
precipitant for thaumatin crystallization. Visualization of the modified
MIPs is challenging. This is primarily owing to their altered consistency
with respect to the original MIPs and also owing to the minute volume
being added. Furthermore, if any precipitate forms within the crystal-
lization drops (as in this instance) visualization is more improbable. The
scale bar corresponds to 50 mm.
lysozyme-MIP and trypsin-MIP. It is also interesting to note
that the ‘hits’ obtained with haemoglobin-MIP often varied
with respect to those obtained with lysozyme-MIP and trypsin-
MIP.
Haemoglobin only yielded new hits with its own cognate
MIP. This is not surprising as it has a greater molecular weight
than lysozyme and trypsin. As such, the cavities formed on
lysozyme-imprinted and trypsin-imprinted MIPs would have
been far too small for the haemoglobin protein molecules.
Conversely, haemoglobin-imprinted MIPs possess cavities
that are larger than lysozyme, thaumatin and trypsin protein
molecules, but do not prevent them from being entrapped
within their cavities (in this instance it is possible that multiple
protein molecules become entrapped within the large cavity).
It appears that screening with an MIP containing larger
cavities is beneficial.
The fact that lysozyme and trypsin are of similar molecular
weight explains why their respective MIPs gave almost iden-
tical results. The lysozyme, trypsin and haemoglobin results
illustrate this clearly. In the case of trypsin, the four ‘hits’
obtained were identical for each MIP tested. Screening trials
with thaumatin were the exception. Although thaumatin was
the only protein tested without its own cognate MIP, its
similarity in molecular weight to trypsin and lysozyme would
lead one to expect overlap in the ‘hits’ observed when
research papers
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Table 2
Trypsin automated optimization trials.
Table detailing the ability of trypsin-MIPs and haemoglobin-MIPs to induce
the nucleation of trypsin crystals under metastable conditions. Each trial was
repeated eight times, with the number indicating the number of repeats where
the nucleating agent facilitated crystal formation whilst the corresponding
controls remained clear. At higher supersaturation both MIPs suffice, whilst at
lower supersaturation (deeper in the metastable zone) the cognate MIP was
more potent and reliable.
PEG concentration
MIP sample 10% 11% 12% 13% 14% 15%
Trypsin-MIP 0 2 6 8 8 8
Haemoglobin-MIP 0 0 1 4 7 8
Table 1
Crystal ‘hits’ when screening with MIPs.
Three MIPs were utilized for the screening of four model proteins. Details of
all crystal ‘hits’ obtained in the presence of MIPs using Crystal Screen HT
whilst the corresponding control drops remained clear are tabulated. The
presence and absence of crystals is indicated by ‘Yes’ and ‘No’, respectively.
MIP sample
Screen condition Haemoglobin-MIP Lysozyme-MIP Trypsin-MIP
Thaumatin at 30 mg ml1
9 No No Yes
16 Yes No No
17 Yes No No
22 Yes No Yes
28 No Yes Yes
30 Yes Yes No
31 Yes No Yes
32 No Yes Yes
33 No Yes Yes
38 No No Yes
62 Yes No Yes
75 No Yes Yes
76 No Yes Yes
80 Yes Yes No
89 Yes No No
Lysozyme at 30 mg ml1
4 Yes Yes Yes
14 No Yes No
16 Yes No No
18 No No Yes
43 Yes No No
45 Yes No No
46 No Yes Yes
60 No Yes Yes
73 Yes Yes No
75 Yes Yes Yes
78 No Yes Yes
94 No No Yes
Trypsin at 50 mg ml1
14 Yes Yes Yes
42 Yes Yes Yes
43 Yes Yes Yes
46 Yes Yes Yes
Haemoglobin at 50 mg ml1
45 Yes No No
82 Yes No No
Figure 3
Pgp3 optimization. (a) A large, single Pgp3 crystal grown under
metastable conditions using a cognate MIP. Single Pgp3 crystals were
obtained using Pgp3-MIPs at dilutions of the original screen ‘hit’ between
50 and 70%. Corresponding controls remained clear. The scale bar
corresponds to 75 mm. (b) Clusters of multiple Pgp3 crystals were
reproducibly obtained using Pgp3-MIPs when the dilution of the original
screen ‘hit’ was greater than 70%. The scale bar corresponds to 100 mm.
screened with lysozyme-MIP and trypsin-MIP. However, very
little correlation was observed. This result is indicative of
factors other than cavity size (such as the cavity shape, charge
etc.) having an influence on the induction of nucleation. The
crystallization cocktail itself can impart a charge on specific
parts of a protein, influencing its ability to form crystal
contacts.
3.3. Automated optimization trials
Table 2 illustrates the automated optimization results
obtained. Both approaches for determining metastability were
demonstrated to be suitable and the insertion of MIPs into
crystallization drops at lower supersaturation reproducibly
prompted the nucleation of trypsin, Pgp3 (Fig. 3) and MIF
crystals (Fig. 4). Theoretically, the deeper into the metastable
zone (i.e. the lower the extent of supersaturation) that nuclei
find themselves, the slower their subsequent growth, resulting
in improved crystal quality. The X-ray diffraction results
obtained support this, with the diffraction resolution limits of
Pgp3 and MIF crystals grown using cognate MIPs at lower
supersaturation being repeatedly as good as, if not better than,
crystals grown using MIPs at higher supersaturation and
crystals grown without MIPs. In the case of Pgp3, the MIP-
grown crystals diffracted to limits between 2.4 and 3.0 A˚
(whilst the control crystals attained 2.8–3.2 A˚ resolution).
For MIF, 1.2 A˚ resolution was obtained compared with control
crystals which diffracted to 1.4 A˚ resolution. No change in
space group or unit-cell parameters was observed.
It was also determined that cognate MIPs were preferable
for optimization trials. When haemoglobin-MIP was utilized
to nucleate trypsin crystals it was not as potent as trypsin-MIP
at lower supersaturation. As such, cognate MIPs, or MIPs
created for a reference protein at as close a molecular weight
as possible to the protein to be crystallized, are recommended
for optimization trials.
As expected, when introduced into drops which would form
crystals in any case, the MIPs only served to increase the rate
and extent of nucleation, resulting in showers of microcrystals.
As such, it is important to exploit the metastable region at
lower supersaturation when optimizing. For example, at the
metastable cusp (the concentration corresponding to condi-
tions at and immediately below the supersolubility curve) the
Pgp3 crystals obtained were clustered together (Fig. 3a). It was
only at lower supersaturation that the crystals obtained were
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Figure 4
MIF optimization. A human macrophage migration inhibitory factor
(MIF) crystal grown using a cognate MIF-MIP. This crystal was grown
under metastable conditions (80% dilution of the original ‘hit’ condition)
which would not normally yield crystals. The scale bar corresponds to
50 mm.
Figure 5
Nucleation in pores/cavities. Schematic illustration (modified from Frenkel, 2006) indicating the potential secondary nucleation sites formed when a
protein crystal nucleates within a pore or cavity on a generic porous nucleating substrate. According to the theoretical model proposed by Page & Sear
(2006), (a) the initial critical nucleus forms at the corner of the pore, (b) the pore is filled followed by subsequent growth out of the pore and (c) a second
critical nucleus forms at the point where the protein aggregate growing out of the pore forms a junction with the nucleant surface. This model is based
upon computer simulations, with the white voids observed being a consequence of the simulation process. A critical nucleus can comprise between ten
and 100 protein molecules. It is possible that another secondary nucleation site can form at the location indicated by the red arrow. At higher levels of
metastability there is sufficient protein to feed both nucleation sites. Furthermore, it is also possible that the protein aggregate growing from the pore
may form a crystal itself.
single and larger in size (Fig. 3b). A potential explanation for
this phenomenon could be the creation of secondary nuclea-
tion sites in close proximity to the cavity which traps the
protein molecules. Studies using atomic force microscopy have
shown that MIP cavities can contain protein aggregates (El-
Sharif et al., 2014). The theoretical model for nucleation within
pores as proposed by Page & Sear (2006) predicts a two-stage
process in which a pore (or cavity) is initially filled with
protein molecules starting at its corners, followed by growth
out of the pore within the bulk solution. When the protein
aggregate that forms within this cavity grows out of it, two
secondary nucleation sites are created at the point where this
aggregate meets the nucleant surface, all within a distance of a
few nanometres (Fig. 5). At higher supersaturation there is
more protein in solution to feed multiple nucleation sites,
whilst at lower supersaturation growth at only one site is
favourable. This phenomenon may be exacerbated by nucle-
ants which have a high surface roughness.
3.4. Commercialization
Having patented the design and application of MIPs for
crystallization, and validated the modified MIPs for high-
throughput trials, the way is now paved for commercialization.
This will involve the production of a library of reference MIPs
of varying molecular weights that could be used for the high-
throughput screening and optimization of any protein, which
is the ultimate goal of this research. As an optimal means for
their application has now been determined, the resulting
commercial product will be very simple to use and can be
dispensed as an additive indiscriminately into trials (with
molecular weight being the sole consideration when selecting
an appropriately imprinted MIP). The MIPs are stored at 4C
and have a long shelf life. At most, they require vortexing if
unused for more than a few weeks. Furthermore, their auto-
mated dispensing has been demonstrated with two robots. The
Mosquito in particular has a fine-bore delivery system and as
such we do not envisage tip blockage being an issue with other
popularly used models.
4. Related literature
The following reference is cited in the Supporting Information
for this article: Asherie (2004).
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